Construction and Validation of an Oxidative Phosphorylation Signature in High‐Grade Glioma and Potential Inhibitors Screening

Glioma is a devastating type of brain tumor with high morbidity and mortality rates. Despite current treatment options, the prognosis for glioma patients remains poor. Metabolic reprograming has emerged as a crucial aspect of tumorigenesis, and the oxidative phosphorylation pathway has received incr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Analytical cellular pathology (Amsterdam) 2024-07, Vol.2024 (1)
Hauptverfasser: Lu, Hanwen, Zhao, Wenpeng, Zhang, Bingchang, Xie, Yuanyuan, He, Jiawei, Yang, Huiying, Wang, Zhanxiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Glioma is a devastating type of brain tumor with high morbidity and mortality rates. Despite current treatment options, the prognosis for glioma patients remains poor. Metabolic reprograming has emerged as a crucial aspect of tumorigenesis, and the oxidative phosphorylation pathway has received increasing attention as a promising target for cancer treatment. In this study, we conducted a comprehensive analysis of transcriptome data to identify differentially expressed genes related to oxidative phosphorylation in glioma. Based on these findings, we developed the first oxidative phosphorylation‐based prognostic and diagnostic signatures and investigated the methylation level of oxidative phosphorylation‐related genes, constructed miRNA–mRNA regulatory networks, and screened potential oxidative phosphorylation pathway inhibitors. Moreover, we analyzed the immune cell infiltration pattern based on oxidative phosphorylation‐related genes’ expression and found that the high‐oxidative phosphorylation group had more inhibitory immune cell infiltration. Overall, this study provides novel insights into the possible molecular mechanisms of oxidative phosphorylation in glioma progression and identifies potential targets for future glioma therapy.
ISSN:2210-7177
2210-7185
DOI:10.1155/2024/2868534